1. Academic Validation
  2. MAP4K4 regulates integrin-FERM binding to control endothelial cell motility

MAP4K4 regulates integrin-FERM binding to control endothelial cell motility

  • Nature. 2015 Mar 26;519(7544):425-30. doi: 10.1038/nature14323.
Philip Vitorino 1 Stacey Yeung 1 Ailey Crow 1 Jesse Bakke 2 Tanya Smyczek 1 Kristina West 3 Erin McNamara 3 Jeffrey Eastham-Anderson 4 Stephen Gould 3 Seth F Harris 5 Chudi Ndubaku 6 Weilan Ye 1
Affiliations

Affiliations

  • 1 Molecular Biology Department, Genentech, Inc., South San Francisco, California 94080, USA.
  • 2 Chemical Biology and Therapeutics Department, St Jude Children's Research Hospital, Memphis, Tennessee 38105, USA.
  • 3 Translational Oncology Department, Genentech, Inc., South San Francisco, California 94080, USA.
  • 4 Pathology Department, Genentech, Inc., South San Francisco, California 94080, USA.
  • 5 Structural Biology Department, Genentech, Inc., South San Francisco, California 94080, USA.
  • 6 Discovery Chemistry Department, Genentech, Inc., South San Francisco, California 94080, USA.
Abstract

Cell migration is a stepwise process that coordinates multiple molecular machineries. Using in vitro angiogenesis screens with short interfering RNA and chemical inhibitors, we define here a MAP4K4-moesin-talin-β1-integrin molecular pathway that promotes efficient plasma membrane retraction during endothelial cell migration. Loss of MAP4K4 decreased membrane dynamics, slowed endothelial cell migration, and impaired angiogenesis in vitro and in vivo. In migrating endothelial cells, MAP4K4 phosphorylates moesin in retracting membranes at sites of focal adhesion disassembly. Epistasis analyses indicated that moesin functions downstream of MAP4K4 to inactivate Integrin by competing with talin for binding to β1-integrin intracellular domain. Consequently, loss of moesin (encoded by the MSN gene) or MAP4K4 reduced adhesion disassembly rate in endothelial cells. Additionally, α5β1-integrin blockade reversed the membrane retraction defects associated with loss of Map4k4 in vitro and in vivo. Our study uncovers a novel aspect of endothelial cell migration. Finally, loss of MAP4K4 function suppressed pathological angiogenesis in disease models, identifying MAP4K4 as a potential therapeutic target.

Figures
Products